Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States
Authors:
- Patricia C. LloydPLPatricia C. Lloyd
- Elizabeth R. SmithESElizabeth R. Smith
- Joann F. GruberJGJoann F. Gruber
- Michelle OndariMOMichelle Ondari
- Hui Lee WongHWHui Lee Wong
- Mao HuMHMao Hu
- Tainya C. ClarkeTainya C. Clarke
- Rowan McEvoyRMRowan McEvoy
- Kandace L. AmendKAKandace L. Amend
- Daniel C. BeachlerDBDaniel C. Beachler
- Cheryl N McMahill-WalravenCMCheryl N McMahill-Walraven
- John D. SeegerJSJohn D. Seeger
Preprint
Abstract
Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes post-licensure. Objective To evaluate health outcomes following bivalent COVID-19 Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273.222) vaccination among individuals 6 months and older in the United States. Design Monthly monitoring of health outcomes from August 2022 to July 2023 in four administrative claims databases. Descriptive analyses monitored vaccine uptake, outcome counts and coadministration of bivalent COVID-19 and influenza vaccines. Sequential analyses tested for elevated risk of each outcome in a prespecified post-vaccination risk interval, or a period of hypothesized elevation based on clinical guidance, compared to a historical baseline. Participants and Exposures Persons 6 months and older who received a bivalent COVID-19 BNT162b2 or mRNA-1273.222 vaccine during the study period, with continuous enrollment in a medical insurance plan from the start of an outcome-specific clean interval to the COVID-19 vaccination date. Vaccines were identified using product-specific codes from medical coding systems. Health Outcomes Twenty outcomes were monitored in BNT162b2 vaccine recipients 6 months-4 years, and mRNA-1273.222 vaccine recipients 6 months-5 years. Twenty-one outcomes were monitored in BNT162b2 vaccine recipients 5-17 years and mRNA-1273.222 vaccine recipients 6-17 years. Eighteen outcomes were monitored in persons 18 years and older for both mRNA vaccines. Results Overall, 13.9 million individuals 6 months and older received a single bivalent COVID-19 mRNA vaccine. The statistical threshold for a signal was met for two outcomes in one database: anaphylaxis following bivalent BNT162b2 and mRNA-1273.222 vaccines in persons 18-64 years and myocarditis/pericarditis following bivalent BNT162b2 vaccines in individuals 18-35 years. There were no signals identified in young children. Conclusions Results were consistent with prior observations from published studies on COVID-19 vaccine safety. This study supports the safety profile of bivalent COVID-19 mRNA vaccines and the conclusion that the benefits of vaccination outweigh the risks.Keywords
All Related Versions
- Published version: Pharmacoepidemiology and Drug Safety, 34 (5), e70151.
This publication has 41 references indexed in Scilit:
- mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and EvaluationCurrent Allergy and Asthma Reports, 2023
- Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the USJAMA Network Open, 2022
- Self-Reported Reactions After COVID-19 VaccinationJournal of Allergy and Clinical Immunology, 2022
- Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021JAMA, 2022
- Association of Facial Paralysis With mRNA COVID-19 VaccinesJAMA Internal Medicine, 2021
- Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021JAMA, 2021
- COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approachProgress in Pediatric Cardiology, 2020
- Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016Journal of Allergy and Clinical Immunology, 2019
- Risk of anaphylaxis after vaccination in children and adultsJournal of Allergy and Clinical Immunology, 2016
- Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataVaccine, 2007